E-MTAB-1063 - Transcription profiling by array of liver samples from LDLR-/- mice to study hepatic response to anti-diabetic drug and dietary lifestyle interventions

Released on 18 April 2013, last updated on 4 November 2014
Mus musculus
Samples (112)
Array (1)
Protocols (7)
Lean male mice were fed a high fat diet (HFD, lard 24% w/w) for 16 weeks. At 9 weeks, when all hallmarks of prediabetes were established, groups of mice were treated with drug (metformin, glibenclamide, sitagliptin, rosiglitazone, pioglitazone, fenofibrate, T0901317, atorvastatin, salicylate or rofecoxib) for another 7 weeks together with the high fat diet. An additional group was switched back to a chow diet (dietary lifestyle intervention) after the first 9 weeks of high fat diet. All groups were compared to a control group receiving HFD alone and to a reference group fed chow (baseline reference) for the entire experimental period (16 weeks).
Experiment types
transcription profiling by array, perturbational
Comprehensive systems analysis reveals supremacy of dietary lifestyle intervention compared to drug therapies in intervening in type 2 diabetes development and complications. Marijana Radonjic, Peter Y. Wielinga, Suzan Wopereis, Thomas Kelder, Varshna S. Goelela, Lars Verschuren, Bianca van der Werff van der Vat, Karin Toet, Johanna H.M. Stroeve, Nicole Cnubben, Teake Kooistra, Ben van Ommen and Robert Kleemann.
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Wagner A, Cohen N, Kelder T, Amit U, Liebman E, Steinberg DM, Radonjic M, Ruppin E. :791 (2015), Europe PMC 25735304
Investigation descriptionE-MTAB-1063.idf.txt
Sample and data relationshipE-MTAB-1063.sdrf.txt
Raw data (1)E-MTAB-1063.raw.1.zip
Processed data (1)E-MTAB-1063.processed.1.zip
Array designA-MEXP-1174.adf.txt